BridgeBio Pharma Inc.
BridgeBio Reports Q3 2025 Financial Results and Business Updates
Summary
BridgeBio Pharma, Inc. reported total third-quarter revenue of $120.7 million, driven by $108.1 million in net product revenue from Attruby, $4.3 million from royalty revenue, and $8.3 million in license and services revenue. The company also announced positive interim analysis results for BBP-418 in LGMD2I/R9 and encaleret in ADH1, with plans to file NDAs in the first half of 2026. BridgeBio ended the quarter with $645.9 million in cash, cash equivalents, and marketable securities. A detailed press release is furnished as Exhibit 99.1.
Profitelligence Alerts
Get alerts for BBIO
Be first to know when BridgeBio Pharma Inc. files with the SEC.
Filing Categories
Advertisement
About BridgeBio Pharma Inc.
BridgeBio Pharma Inc. is a cutting-edge biotechnology company focused on discovering, developing, and delivering transformative medicines for patients with genetic diseases. The company's primary purpose is to bridge the gap in medical research and bring breakthrough therapies to those with rare and often overlooked genetic disorders. By utilizing a targeted approach, BridgeBio Pharma Inc. works across multiple sectors including dermatology, oncology, cardiology, neurology, and endocrinology. The company partners with academic institutions, research organizations, and industry leaders to harness the latest scientific advancements in genomics and biotechnology. Established with a mission to translate genetic research into real-world medical solutions, BridgeBio Pharma Inc. plays a significant role in the biopharmaceutical market. It is heavily involved in the early and late stages of drug development, positioning itself as a key player in the quest to address unmet medical needs. This focus on genetic-centric therapies underlines its importance in the rapidly evolving landscape of biotechnology and personalized medicine.
Official SEC Documents
Advertisement